Upcoming IPO: Senores Pharma To Open Rs 582 Crore Public Issue For Subscription Tomorrow; Check Details

The Senores Pharmaceuticals Ltd IPO is set to open for public subscription on Friday, December 20. Targeting regulated markets such as the US, Canada, and the UK, alongside emerging markets, Senores Pharmaceuticals has built a robust product portfolio of 55 pharmaceutical offerings across key therapeutic areas, including antibiotics and antifungal treatments.

The IPO is poised to raise over Rs 582 crore through a mix of fresh issue and an offer-for-sale (OFS), and the company's shares will debut on both the BSE and NSE. Here's a detailed breakdown of everything you need to know.

IPO Dates

The IPO opens on December 20 and closes on December 24, giving investors four days to subscribe to the public issue.

Price Band

The price band has been set between Rs 372 and Rs 391 per share, making it accessible for retail and institutional investors alike.

IPO Size and Structure

The total issue size is pegged at Rs 582.11 crore at the upper end of the price band. The breakdown includes fresh issue of 1.28 crore equity shares, amounting to Rs 500 crore, and offer-for-sale (OFS) of 21 lakh equity shares, aggregating to Rs 82.11 crore.

Lot Size and Minimum Investment

The lot size for the IPO is 38 shares, requiring a minimum investment of Rs 14,858 at the upper price band.

Offer-for-Sale Details

The promoters of the company, Swapnil Shah, Ashokkumar Barot, and Sangeeta Barot, will offload 11 lakh equity shares, while another 10 lakh shares will be sold by shareholder Prakash M Sanghvi as part of the OFS.

Objectives of the IPO

The funds raised from the IPO will be utilized for several strategic purposes, including investment in the company's subsidiaries, repayment or pre-payment of certain borrowings, meeting working capital requirements, funding inorganic growth through acquisitions and strategic initiatives, and General corporate purposes.

Reservation for Investor Categories

Qualified Institutional Buyers (QIB) reserved not less than 75% of the shares. Non-Institutional Investors (NII) allocated not more than 15% of the shares, and retail investors allocated not more than 10% of the shares.

Allotment and Listing Details

The IPO allotment is expected to be finalized on December 26. The shares are likely to debut on the stock exchanges on December 30, listing on both the BSE and NSE.

Stakeholders

Equirus Capital, Ambit Private Limited, and Nuvama Wealth Management are the book-running lead managers, and Link Intime India Private Ltd is the registrar.

Grey Market Premium (GMP)

The IPO has been generating buzz in the grey market, with shares commanding a GMP of Rs 150. This suggests that Senores Pharmaceuticals shares are trading at Rs 541 apiece, reflecting a premium of 38.36% over the upper price band of Rs 391.

Senores Pharmaceuticals is known for manufacturing a range of pharmaceutical products, primarily targeting regulated markets such as the US, Canada, and the UK. With a portfolio of 55 products as of September 30, 2024, the company has established itself in key therapeutic segments, including antibiotics and antifungal treatments.

The company's focus on regulated markets gives it a competitive edge, ensuring compliance with stringent quality standards and fostering trust among global clients.